Table 3. Summary ORs and 95% CI of microRNA-196a2 rs11614913 polymorphisms and CHD risk.
| Locus | N* | Allele | Recessive | Dominant | Homozygote | Heterozygote | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) P | I2(%) | OR (95%CI) P | I2(%) | OR (95%CI) P | I2(%) | OR (95%CI) P | I2(%) | OR (95%CI) P | I2(%) | ||
| Total | 7 | 1.03 (0.98-1.09) 0.252 | 0 | 0.99 (0.90-1.08) 0.801 | 6.0 | 1.08 (1.00-1.17) 0.046 | 27.3 | 1.05 (0.95-1.16) 0.370 | 0 | 1.10 (1.01-1.19) 0.029 | 40.0 |
| Source of controls | |||||||||||
| Population | 2 | 1.03 (0.91-1.17) 0.615 | 60.3 | 0.95 (0.69-1.30) 0.736 | 81.3 | 1.13 (1.00-1.28) 0.042 | 0 | 1.05 (0.80-1.39) 0.711 | 64.8 | 1.15 (1.01-1.30) 0.032 | 0 |
| Hospital | 5 | 1.02 (0.95-1.09) 0.671 | 0 | 0.98 (0.87-1.11) 0.793 | 0 | 1.05 (0.94-1.17) 0.389 | 44.8 | 1.01 (0.88-1.17) 0.863 | 0 | 1.04 (0.87-1.24) 0.666 | 55.4 |
| Method | |||||||||||
| Taqman | 3 | 1.04 (0.97-1.11) 0.242 | 25.3 | 0.95 (0.78-1.16) 0.604 | 63.9 | 1.13 (1.01-1.25) 0.030 | 0 | 1.08 (0.94-1.23) 0.299 | 34.2 | 1.15 (1.02-1.28) 0.017 | 0 |
| PCR-RFLP | 3 | 1.01 (0.91-1.12) 0.847 | 30.4 | 1.04 (0.87-1.25) 0.661 | 0 | 0.98 (0.74-1.29) 0.867 | 68.5 | 1.02 (0.83-1.25) 0.874 | 0 | 0.95 (0.69-1.32) 0.775 | 72.4 |
| Age and sex matched | 5 | 1.03 (0.97-1.09) 0.315 | 30.4 | 0.99 (0.90-1.09) 0.825 | 28.9 | 1.07 (0.93-1.22) 0.342 | 50.4 | 1.05 (0.94-1.18) 0.387 | 18.0 | 1.08 (0.93-1.26) 0.316 | 57.3 |
* Numbers of comparisons. PCR-RFLP: polymerase chain reaction-based restriction fragment length polymorphism.